Vertex Earnings Reports

Vertex Pharmaceuticals reported strong Q4 2024 results with a 16% increase in product revenue, reaching $2.91 billion, driven by the continued performance of TRIKAFTA/KAFTRIO. However, net income declined slightly due to increased R&D and SG&A expenses.

Vertex Pharmaceuticals reported a 6% increase in product revenue to $2.65 billion for Q2 2024, driven by TRIKAFTA/KAFTRIO. The company raised its full-year product revenue guidance to $10.65 to $10.85 billion. Key advancements include FDA acceptance of NDA for vanzacaftor triple in CF and suzetrigine for acute pain.

Vertex Pharmaceuticals reported a 14% increase in product revenue to $2.49 billion for Q2 2023, driven by strong uptake of TRIKAFTA/KAFTRIO internationally and continued performance in the U.S. The company raised its full-year 2023 revenue guidance to $9.7 to $9.8 billion.